DK1146874T3 - Vitronectinreceptoragonist - Google Patents

Vitronectinreceptoragonist

Info

Publication number
DK1146874T3
DK1146874T3 DK99960647T DK99960647T DK1146874T3 DK 1146874 T3 DK1146874 T3 DK 1146874T3 DK 99960647 T DK99960647 T DK 99960647T DK 99960647 T DK99960647 T DK 99960647T DK 1146874 T3 DK1146874 T3 DK 1146874T3
Authority
DK
Denmark
Prior art keywords
receptor agonist
vitronectin receptor
vitronectin
agonist
receptor
Prior art date
Application number
DK99960647T
Other languages
Danish (da)
English (en)
Inventor
William H Miller
Peter J Manley
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Application granted granted Critical
Publication of DK1146874T3 publication Critical patent/DK1146874T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/243Platinum; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
DK99960647T 1998-12-04 1999-12-03 Vitronectinreceptoragonist DK1146874T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11090398P 1998-12-04 1998-12-04
EP99960647A EP1146874B1 (en) 1998-12-04 1999-12-03 Vitronectin receptor antagonist

Publications (1)

Publication Number Publication Date
DK1146874T3 true DK1146874T3 (da) 2005-01-31

Family

ID=22335565

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99960647T DK1146874T3 (da) 1998-12-04 1999-12-03 Vitronectinreceptoragonist

Country Status (39)

Country Link
US (1) US6495560B1 (bg)
EP (1) EP1146874B1 (bg)
JP (1) JP4481504B2 (bg)
KR (1) KR100620485B1 (bg)
CN (1) CN1147300C (bg)
AP (1) AP1534A (bg)
AR (1) AR035006A1 (bg)
AT (1) ATE277043T1 (bg)
AU (1) AU754408B2 (bg)
BG (1) BG65118B1 (bg)
BR (1) BR9915879A (bg)
CA (1) CA2353415A1 (bg)
CO (1) CO5150166A1 (bg)
CZ (1) CZ20011963A3 (bg)
DE (1) DE69920518T2 (bg)
DK (1) DK1146874T3 (bg)
DZ (1) DZ2954A1 (bg)
EA (1) EA003254B1 (bg)
EG (1) EG24025A (bg)
ES (1) ES2229798T3 (bg)
HK (1) HK1042037B (bg)
HU (1) HUP0104804A3 (bg)
ID (1) ID28811A (bg)
IL (2) IL143390A0 (bg)
MA (1) MA25265A1 (bg)
NO (1) NO318895B1 (bg)
NZ (1) NZ511876A (bg)
OA (1) OA11724A (bg)
PE (1) PE20001563A1 (bg)
PL (1) PL195973B1 (bg)
PT (1) PT1146874E (bg)
SI (1) SI1146874T1 (bg)
SK (1) SK7452001A3 (bg)
TR (1) TR200101654T2 (bg)
TW (1) TW482673B (bg)
UA (1) UA71586C2 (bg)
UY (1) UY25824A1 (bg)
WO (1) WO2000033838A1 (bg)
ZA (1) ZA200104398B (bg)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1289960A2 (en) * 2000-06-15 2003-03-12 Pharmacia Corporation Cycloalkyl alkanoic acids as integrin receptor antagonists
JP2004513953A (ja) * 2000-10-24 2004-05-13 メルク エンド カムパニー インコーポレーテッド ジベンズオキサゼピンαVインテグリン受容体アンタゴニスト
ATE530183T1 (de) 2001-01-29 2011-11-15 Ortho Mcneil Pharm Inc Substituierte indole und ihre verwendung als integrin-antagonisten
US6872730B2 (en) 2001-04-27 2005-03-29 3-Dimensional Pharmaceuticals, Inc. Substituted benzofurans and benzothiophenes, methods of making and methods of use as integrin antagonists
US20040224986A1 (en) 2002-08-16 2004-11-11 Bart De Corte Piperidinyl targeting compounds that selectively bind integrins
JP2006516144A (ja) 2002-12-20 2006-06-22 ファルマシア・コーポレーション インテグリン受容体アンタゴニスト誘導体としてのチアゾール化合物
GB0319069D0 (en) * 2003-08-14 2003-09-17 Glaxo Group Ltd Therapeutically useful compounds
EP1841406A4 (en) * 2004-12-21 2008-06-25 Smithkline Beecham Corp METHOD AND FORMULATIONS
SG186989A1 (en) 2010-07-14 2013-02-28 Novartis Ag Ip receptor agonist heterocyclic compounds
AR089698A1 (es) 2012-01-13 2014-09-10 Novartis Ag Compuestos heterociclicos antagonistas del receptor ip
US9604981B2 (en) 2013-02-13 2017-03-28 Novartis Ag IP receptor agonist heterocyclic compounds
ES2957460T3 (es) 2013-09-24 2024-01-19 Fujifilm Corp Composición farmacéutica de un compuesto que contiene nitrógeno o una sal del mismo, o complejo de metal de los mismos

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2687154B1 (fr) * 1992-02-07 1995-05-12 Rhone Poulenc Rorer Sa Nouveau derive de l'isoindolinone, sa preparation et les compositions pharmaceutiques qui le contiennent.
DK0910563T3 (da) 1995-06-29 2003-09-01 Smithkline Beecham Corp Integrinreceptorantagonister
AU4109297A (en) * 1996-09-27 1998-04-17 Merkler, H. Tank for liquids, particularly for chemically aggressive liquids
EP0946180A4 (en) 1996-10-07 2003-07-23 Smithkline Beecham Corp METHODS FOR STIMULATING BONE FORMATION
UY24949A1 (es) 1997-04-08 2001-04-30 Smithkline Beecham Corp Compuestos calcilíticos

Also Published As

Publication number Publication date
EA003254B1 (ru) 2003-02-27
AU754408B2 (en) 2002-11-14
HK1042037B (zh) 2005-07-29
IL143390A0 (en) 2002-04-21
HUP0104804A2 (hu) 2002-05-29
AP1534A (en) 2006-01-09
NO20012732D0 (no) 2001-06-01
CN1147300C (zh) 2004-04-28
JP2003523931A (ja) 2003-08-12
NZ511876A (en) 2004-02-27
EG24025A (en) 2008-03-26
AU1750200A (en) 2000-06-26
BR9915879A (pt) 2002-02-13
CN1334730A (zh) 2002-02-06
ID28811A (id) 2001-07-05
UY25824A1 (es) 2001-07-31
CO5150166A1 (es) 2002-04-29
ATE277043T1 (de) 2004-10-15
EP1146874B1 (en) 2004-09-22
BG105651A (bg) 2002-02-28
SI1146874T1 (en) 2005-04-30
SK7452001A3 (en) 2001-12-03
ES2229798T3 (es) 2005-04-16
PL195973B1 (pl) 2007-11-30
DE69920518T2 (de) 2005-09-22
HK1042037A1 (en) 2002-08-02
UA71586C2 (en) 2004-12-15
DE69920518D1 (de) 2004-10-28
CZ20011963A3 (cs) 2001-11-14
CA2353415A1 (en) 2000-06-15
PT1146874E (pt) 2005-02-28
DZ2954A1 (fr) 2004-06-20
NO318895B1 (no) 2005-05-18
OA11724A (en) 2005-01-26
HUP0104804A3 (en) 2002-12-28
WO2000033838A1 (en) 2000-06-15
TW482673B (en) 2002-04-11
BG65118B1 (bg) 2007-03-30
KR100620485B1 (ko) 2006-09-13
US6495560B1 (en) 2002-12-17
EA200100618A1 (ru) 2001-12-24
MA25265A1 (fr) 2001-10-01
KR20010080669A (ko) 2001-08-22
IL143390A (en) 2006-07-05
NO20012732L (no) 2001-08-01
AR035006A1 (es) 2004-04-14
JP4481504B2 (ja) 2010-06-16
PE20001563A1 (es) 2001-02-09
EP1146874A4 (en) 2002-06-05
ZA200104398B (en) 2002-05-29
PL348702A1 (en) 2002-06-03
TR200101654T2 (tr) 2002-03-21
EP1146874A1 (en) 2001-10-24

Similar Documents

Publication Publication Date Title
IS5706A (is) Adenosín A3 viðtakastillar
DK1019075T3 (da) Beta2-Adrenerge receptoragonister
PT1192169E (pt) C-pirazoles agonistas do receptor a2a
DE69921351D1 (de) 4-aroyl-piperidin-ccr-3 rezeptor antagonisten iii
ATE312089T1 (de) Vitronektin rezeptor antagonisten
CY2010003I1 (el) Αγωνιστες των βητα-2 αδρενεργικων υποδοχεων
NO20012411D0 (no) Pyrrolidin-derivater-CCR-3-reseptorantagonister
NO965608D0 (no) Vitronectin-reseptor-antagonister
NO993350D0 (no) Vitronectin-reseptor-antagonister
NO20004503L (no) Vitronectin-reseptor-antagonister
DE69919171D1 (de) Muskarin-rezeptor antagonisten
NO20001514D0 (no) Vitronectin-reseptor-antagonist
ID24726A (id) Antagonis-antagonis reseptor trombin
NO20001515D0 (no) Vitronektin reseptor-antagonist
NO20013997D0 (no) Reseptoranalyse
NO20001407D0 (no) Vitronectin-reseptor-antagonister
DK1146874T3 (da) Vitronectinreceptoragonist
ID26086A (id) Ligan-ligan reseptor 5ht1 azabisiklik
NO20021113D0 (no) Vitronectin-reseptor-antagonister
NO20010620D0 (no) Vitronektinreseptor-antagonister
NO20021295L (no) Nikotinsyreacetylcholin-reseptor
NO20010353D0 (no) IL-8 reseptor-antagonist
DK1218005T3 (da) Vitronectinreptorantagonister
DE69830671D1 (de) Integrin-rezeptor-antagonisten